» Articles » PMID: 17624581

Adaptive Landscapes and Emergent Phenotypes: Why Do Cancers Have High Glycolysis?

Overview
Publisher Springer
Date 2007 Jul 13
PMID 17624581
Citations 112
Authors
Affiliations
Soon will be listed here.
Abstract

Investigating the causes of increased aerobic glycolysis in tumors (Warburg Effect) has gone in and out of fashion many times since it was first described almost a century ago. The field is currently in ascendance due to two factors. Over a million FDG-PET studies have unequivocally identified increased glucose uptake as a hallmark of metastatic cancer in humans. These observations, combined with new molecular insights with HIF-1alpha and c-myc, have rekindled an interest in this important phenotype. A preponderance of work has been focused on the molecular mechanisms underlying this effect, with the expectation that a mechanistic understanding may lead to novel therapeutic approaches. There is also an implicit assumption that a mechanistic understanding, although fundamentally reductionist, will nonetheless lead to a more profound teleological understanding of the need for altered metabolism in invasive cancers. In this communication, we describe an alternative approach that begins with teleology; i.e. adaptive landscapes and selection pressures that promote emergence of aerobic glycolysis during the somatic evolution of invasive cancer. Mathematical models and empirical observations are used to define the adaptive advantage of aerobic glycolysis that would explain its remarkable prevalence in human cancers. These studies have led to the hypothesis that increased consumption of glucose in metastatic lesions is not used for substantial energy production via Embden-Meyerhoff glycolysis, but rather for production of acid, which gives the cancer cells a competitive advantage for invasion. Alternative hypotheses, wherein the glucose is used for generation of reducing equivalents (NADPH) or anabolic precursors (ribose) are also discussed.

Citing Articles

FKBP4 promotes glycolysis and hepatocellular carcinoma progression via p53/HK2 axis.

Zeng Z, Xu S, Wang R, Han X Sci Rep. 2024; 14(1):26893.

PMID: 39505995 PMC: 11542027. DOI: 10.1038/s41598-024-78383-6.


Modeling tumors as complex ecosystems.

Aguade-Gorgorio G, Anderson A, Sole R iScience. 2024; 27(9):110699.

PMID: 39280631 PMC: 11402243. DOI: 10.1016/j.isci.2024.110699.


Emerging multimodality imaging techniques for the pulmonary circulation.

Rajagopal S, Bogaard H, Elbaz M, Freed B, Remy-Jardin M, van Beek E Eur Respir J. 2024; 64(4).

PMID: 39209480 PMC: 11525339. DOI: 10.1183/13993003.01128-2024.


Modeling tumors as species-rich ecological communities.

Aguade-Gorgorio G, Anderson A, Sole R bioRxiv. 2024; .

PMID: 38712062 PMC: 11071393. DOI: 10.1101/2024.04.22.590504.


pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.

Dutta D, Ray P, De A, Ghosh A, Hazra R, Ghosh P PLoS One. 2024; 19(4):e0297749.

PMID: 38687749 PMC: 11060587. DOI: 10.1371/journal.pone.0297749.


References
1.
Schornack P, Gillies R . Contributions of cell metabolism and H+ diffusion to the acidic pH of tumors. Neoplasia. 2003; 5(2):135-45. PMC: 1502399. DOI: 10.1016/s1476-5586(03)80005-2. View

2.
Jang A, Hill R . An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. Clin Exp Metastasis. 1997; 15(5):469-83. DOI: 10.1023/a:1018470709523. View

3.
KROGH A . The number and distribution of capillaries in muscles with calculations of the oxygen pressure head necessary for supplying the tissue. J Physiol. 1919; 52(6):409-15. PMC: 1402716. DOI: 10.1113/jphysiol.1919.sp001839. View

4.
KROGH A . The rate of diffusion of gases through animal tissues, with some remarks on the coefficient of invasion. J Physiol. 1919; 52(6):391-408. PMC: 1402717. DOI: 10.1113/jphysiol.1919.sp001838. View

5.
Kelloff G, Hoffman J, Johnson B, Scher H, Siegel B, Cheng E . Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005; 11(8):2785-808. DOI: 10.1158/1078-0432.CCR-04-2626. View